Fig. 1
From: Infographic: teprotumumab for the treatment of active thyroid eye disease
Teprotumumab is a monoclonal antibody therapy targeting insulin-like growth factor-1 receptor (IGF-IR) for thyroid eye disease (TED). Teprotumumab is an alternative to traditional immunosuppression [1, 2]. This infographic summarises the design and results of the multicentre phase III “OPTIC” trial: Treatment of Graves’ Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Protumumab Infusions in a Randomized, Placebo-Controlled, Trial, Investigating Clinical Efficacy. This trial evaluated the efficacy and safety of teprotumumab in active TED compared to placebo [3]. Teprotumumab reduced proptosis, Clinical Activity Score, diplopia and improved patient reported quality of life [3]. Created in BioRender. Berman, G. (2026) https://BioRender.com/yb3ap06.
